Reprogramming cancer cells: A novel approach for cancer therapy or a tool for disease-modeling?

Cancer Letters

Volumn 369, Issue 1, 2015, Pages 1-8

  Yilmazer, Açelya ^a   de Lázaro, Irene ^b,c   Taheri, Hadiseh ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; Cell reprogramming; Epigenetics; IPS cells; Transcription factors

Indexed keywords

TRANSCRIPTION FACTOR;

CANCER CELL; CANCER THERAPY; CARCINOGENESIS; CARCINOGENICITY; CELL FATE; CELL REGENERATION; CHROMATIN; DISEASE MODEL; EPIGENETICS; GENE ACTIVATION; GENE OVEREXPRESSION; HUMAN; NONHUMAN; NUCLEAR REPROGRAMMING; PATHOLOGY; PHYSIOLOGICAL PROCESS; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SHORT SURVEY; TUMOR GROWTH; ANIMAL; BIOLOGICAL MODEL; CANCER STEM CELL; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; NEOPLASMS; PHYSIOLOGY; TUMOR CELL CULTURE;

ANIMALS; CARCINOGENESIS; CELLULAR REPROGRAMMING; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MODELS, BIOLOGICAL; NEOPLASMS; NEOPLASTIC STEM CELLS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 84943454575     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.06.027     Document Type: Review

References (91)

1. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
2. Park I.H., Arora N., Huo H., Maherali N., Ahfeldt T., Shimamura A., et al. Disease-specific induced pluripotent stem cells. Cell 2008, 134:877-886.
3. Merkle F.T., Eggan K. Modeling human disease with pluripotent stem cells: from genome association to function. Cell Stem Cell 2013, 12:656-668.
4. Sng J., Lufkin T. Emerging stem cell therapies: treatment, safety, and biology. Stem Cells Int 2012, 2012:521343.
5. Sharma S., Kelly T.K., Jones P.A. Epigenetics in cancer. Carcinogenesis 2010, 31:27-36.
6. Gurdon J.B., Laskey R.A., Reeves O.R. The developmental capacity of nuclei transplanted from keratinized skin cells of adult frogs. J. Embryol. Exp. Morphol 1975, 34:93-112.
7. Miller R.A., Ruddle F.H. Pluripotent teratocarcinoma-thymus somatic cell hybrids. Cell 1976, 9:45-55.
8. Chun Y.S., Chaudhari P., Jang Y.Y. Applications of patient-specific induced pluripotent stem cells; focused on disease modeling, drug screening and therapeutic potentials for liver disease. Int. J. Biol. Sci 2010, 6:796-805.
9. Bellin M., Marchetto M.C., Gage F.H., Mummery C.L. Induced pluripotent stem cells: the new patient?. Nat. Rev. Mol. Cell Biol 2012, 13:713-726.
10. Lin S.L. Concise review: deciphering the mechanism behind induced pluripotent stem cell generation. Stem Cells 2011, 29:1645-1649.
11. Liang G., Zhang Y. Embryonic stem cell and induced pluripotent stem cell: an epigenetic perspective. Cell Res 2013, 23:49-69.
12. Buganim Y., Faddah D.A., Cheng A.W., Itskovich E., Markoulaki S., Ganz K., et al. Single-cell expression analyses during cellular reprogramming reveal an early stochastic and a late hierarchic phase. Cell 2012, 150:1209-1222.
13. Buganim Y., Faddah D.A., Jaenisch R. Mechanisms and models of somatic cell reprogramming. Nat. Rev. Genet 2013, 14:427-439.
14. Chung K.M., Kolling F.W.T., Gajdosik M.D., Burger S., Russell A.C., Nelson C.E. Single cell analysis reveals the stochastic phase of reprogramming to pluripotency is an ordered probabilistic process. PLoS ONE 2014, 9:e95304.
15. Graf T. Historical origins of transdifferentiation and reprogramming. Cell Stem Cell 2011, 9:504-516.
16. Newman A.M., Cooper J.B. Lab-specific gene expression signatures in pluripotent stem cells. Cell Stem Cell 2010, 7:258-262.
17. Ruiz S., Diep D., Gore A., Panopoulos A.D., Montserrat N., Plongthongkum N., et al. Identification of a specific reprogramming-associated epigenetic signature in human induced pluripotent stem cells. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:16196-16201.
18. Kim K., Doi A., Wen B., Ng K., Zhao R., Cahan P., et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010, 467:285-290.
19. Kobayashi H., Kikyo N. Epigenetic regulation of open chromatin in pluripotent stem cells. Transl. Res 2015, 165:18-27.
20. Papp B., Plath K. Epigenetics of reprogramming to induced pluripotency. Cell 2013, 152:1324-1343.
21. Feng B., Ng J.H., Heng J.C., Ng H.H. Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells. Cell Stem Cell 2009, 4:301-312.
22. Robinton D.A., Daley G.Q. The promise of induced pluripotent stem cells in research and therapy. Nature 2012, 481:295-305.
23. Lu J., Kong X., Luo C., Li K.K. Application of epigenome-modifying small molecules in induced pluripotent stem cells. Med. Res. Rev 2013, 33:790-822.
24. Firestone A.J., Chen J.K. Controlling destiny through chemistry: small-molecule regulators of cell fate. ACS Chem. Biol 2010, 5:15-34.
25. Yaniv M. Chromatin remodeling: from transcription to cancer. Cancer Genet 2014, 207(9):352-357.
26. He L., Liu H., Tang L. SWI/SNF chromatin remodeling complex: a new cofactor in reprogramming. Stem Cell Rev 2012, 8:128-136.
27. Narayanan R., Tuoc T.C. Roles of chromatin remodeling BAF complex in neural differentiation and reprogramming. Cell Tissue Res 2014, 356:575-584.
28. Apostolou E., Hochedlinger K. Chromatin dynamics during cellular reprogramming. Nature 2013, 502:462-471.
29. Singhal N., Graumann J., Wu G., Araúzo-Bravo M.J., Han D.W., Greber B., et al. Chromatin-remodeling components of the BAF complex facilitate reprogramming. Cell 2010, 141:943-955.
30. Di Croce L., Helin K. Transcriptional regulation by Polycomb group proteins. Nat. Struct. Mol. Biol 2013, 20:1147-1155.
31. Sauvageau M., Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 2010, 7:299-313.
32. Fragola G., Germain P.-L., Laise P., Cuomo A., Blasimme A., Gross F., et al. Cell reprogramming requires silencing of a core subset of polycomb targets. PLoS Genet 2013, 9:e1003292.
33. Luna-Zurita L., Bruneau B.G. Chromatin modulators as facilitating factors in cellular reprogramming. Curr. Opin. Genet. Dev 2013, 23:556-561.
34. Meshorer E., Yellajoshula D., George E., Scambler P.J., Brown D.T., Misteli T. Hyperdynamic plasticity of chromatin proteins in pluripotent embryonic stem cells. Dev. Cell 2006, 10:105-116.
35. Krejci J., Uhlirova R., Galiova G., Kozubek S., Smigova J., Bartova E. Genome-wide reduction in H3K9 acetylation during human embryonic stem cell differentiation. J. Cell. Physiol 2009, 219:677-687.
36. Sridharan R., Gonzales-Cope M., Chronis C., Bonora G., McKee R., Huang C., et al. Proteomic and genomic approaches reveal critical functions of H3K9 methylation and heterochromatin protein-1gamma in reprogramming to pluripotency. Nat. Cell Biol 2013, 15:872-882.
37. Mansour A.A., Gafni O., Weinberger L., Zviran A., Ayyash M., Rais Y., et al. The H3K27 demethylase Utx regulates somatic and germ cell epigenetic reprogramming. Nature 2012, 488:409-413.
38. Okita K., Ichisaka T., Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007, 448:313-317.
39. Hezroni H., Sailaja B.S., Meshorer E. Pluripotency-related, valproic acid (VPA)-induced genome-wide histone H3 lysine 9 (H3K9) acetylation patterns in embryonic stem cells. J. Biol. Chem 2011, 286:35977-35988.
40. Huangfu D., Maehr R., Guo W., Eijkelenboom A., Snitow M., Chen A.E., et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat. Biotechnol 2008, 26:795-797.
41. Huangfu D., Osafune K., Maehr R., Guo W., Eijkelenboom A., Chen S., et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat. Biotechnol 2008, 26:1269-1275.
42. dos Santos R.L., Tosti L., Radzisheuskaya A., Caballero I.M., Kaji K., Hendrich B., et al. MBD3/NuRD facilitates induction of pluripotency in a context-dependent manner. Cell Stem Cell 2014, 15:102-110.
43. Liang G., He J., Zhang Y. Kdm2b promotes induced pluripotent stem cell generation by facilitating gene activation early in reprogramming. Nat. Cell Biol 2012, 14:457-466.
44. Mikkelsen T.S., Hanna J., Zhang X., Ku M., Wernig M., Schorderet P., et al. Dissecting direct reprogramming through integrative genomic analysis. Nature 2008, 454:49-55.
45. Feinberg A.P., Tycko B. The history of cancer epigenetics. Nat. Rev. Cancer 2004, 4:143-153.
46. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 2011, 11:726-734.
47. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet 2007, 8:286-298.
48. Jones S., Wang T.-L., Shih I.-M., Mao T.-L., Nakayama K., Roden R., et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010, 330:228-231.
49. Dawson M.A., Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2013, 150:12-27.
50. Morin R.D., Mendez-Lago M., Mungall A.J., Goya R., Mungall K.L., Corbett R.D., et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011, 476:298-303.
51. van Haaften G., Dalgliesh G.L., Davies H., Chen L., Bignell G., Greenman C., et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet 2009, 41:521-523.
52. Richly H., Aloia L., Di Croce L. Roles of the polycomb group proteins in stem cells and cancer. Cell Death Dis 2011, 2:e204.
53. Wilson B.G., Roberts C.W.M. SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 2011, 11:481-492.
54. Yamamoto Y., Abe A., Emi N. Clarifying the impact of polycomb complex component disruption in human cancers. Mol. Cancer Res 2014, 12:479-484.
55. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38-51.
56. Suvà M.L., Riggi N., Bernstein B.E. Epigenetic reprogramming in cancer. Science 2013, 339:1567-1570.
57. Hochedlinger K., Blelloch R., Brennan C., Yamada Y., Kim M., Chin L., et al. Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev 2004, 18:1875-1885.
58. Kumano K., Arai S., Kurokawa M. Generation of iPS cells from normal and malignant hematopoietic cells. Int. J. Hematol 2013, 98:145-152.
59. Lin S.-L., Chang D.C., Chang-Lin S., Lin C.-H., Wu D.T.S., Chen D.T., et al. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA 2008, 14:2115-2124.
60. Utikal J., Maherali N., Kulalert W., Hochedlinger K. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J. Cell Sci 2009, 122:3502-3510.
61. Fernandez Tde S., de Souza Fernandez C., Mencalha A.L. Human induced pluripotent stem cells from basic research to potential clinical applications in cancer. Biomed Res. Int 2013, 2013:11.
62. Richard S., Sebastian G., In-Hyun P., Gareth J.S. Modelling human disease with pluripotent stem cells. Curr. Gene Ther 2013, 13:99-110.
63. Blelloch R.H., Hochedlinger K., Yamada Y., Brennan C., Kim M., Mintz B., et al. Nuclear cloning of embryonal carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:13985-13990.
64. Choong P.F., Teh H.X., Teoh H.K., Ong H.K., Choo K.B., Sugii S., et al. Heterogeneity of osteosarcoma cell lines led to variable responses in reprogramming, in. Int. J. Med. Sci 2014, 1154-1160.
65. Liu Y., Cheng H., Gao S., Lu X., He F., Hu L., et al. Reprogramming of MLL-AF9 leukemia cells into pluripotent stem cells. Leukemia 2014, 28:1071-1080.
66. Postovit L.-M., Margaryan N.V., Seftor E.A., Kirschmann D.A., Lipavsky A., Wheaton W.W., et al. Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:4329-4334.
67. Carette J.E., Pruszak J., Varadarajan M., Blomen V.A., Gokhale S., Camargo F.D., et al. Generation of iPSCs from cultured human malignant cells. Blood 2010, 115:4039-4042.
68. Kim J., Hoffman J.P., Alpaugh R.K., Rhim A.D., Reichert M., Stanger B.Z., et al. An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression. Cell Rep 2013, 3:2088-2099.
69. Kumano K., Arai S., Hosoi M., Taoka K., Takayama N., Otsu M., et al. Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood 2012, 119:6234-6242.
70. Mathieu J., Zhang Z., Zhou W., Wang A.J., Heddleston J.M., Pinna C.M.A., et al. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 2011, 71:4640-4652.
71. Nagai K.-I., Ishii H., Miyoshi N., Hoshino H., Saito T., Sato T., et al. Long-term culture following ES-like gene-induced reprogramming elicits an aggressive phenotype in mutated cholangiocellular carcinoma cells. Biochem. Biophys. Res. Commun 2010, 395:258-263.
72. Allegrucci C., Rushton M., Dixon J., Sottile V., Shah M., Kumari R., et al. Epigenetic reprogramming of breast cancer cells with oocyte extracts. Mol. Cancer 2011, 10:1-14.
73. Lai J., Kong C.M., Mahalingam D., Xie X., Wang X. Elite model for the generation of induced pluripotent cancer cells (iPCs). PLoS ONE 2013, 8:e56702.
74. Mahalingam D., Kong C.M., Lai J., Tay L.L., Yang H., Wang X. Reversal of aberrant cancer methylome and transcriptome upon direct reprogramming of lung cancer cells. Sci. Rep 2012, 2.
75. Miyoshi N., Ishii H., Nagai K.-I., Hoshino H., Mimori K., Tanaka F., et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:40-45.
76. Zhang J., Espinoza L.A., Kinders R.J., Lawrence S.M., Pfister T.D., Zhou M., et al. NANOG modulates stemness in human colorectal cancer. Oncogene 2013, 32:4397-4405.
77. Zhang X., Cruz F.D., Terry M., Remotti F., Matushansky I. Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. Oncogene 2013, 32:2249-2260.
78. Siller R., Greenhough S., Park I.H., Sullivan G.J. Modelling human disease with pluripotent stem cells. Curr. Gene Ther 2013, 13:99-110.
79. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
80. Miller D.M., Thomas S.D., Islam A., Muench D., Sedoris K. c-Myc and cancer metabolism. Clin. Cancer Res 2012, 18:5546-5553.
81. Boumahdi S., Driessens G., Lapouge G., Rorive S., Nassar D., Le Mercier M., et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature 2014, 511:246-250.
82. Leng Z., Tao K., Xia Q., Tan J., Yue Z., Chen J., et al. Krüppel-like factor 4 acts as an oncogene in colon cancer stem cell-enriched spheroid cells. PLoS ONE 2013, 8:e56082.
83. Matsuoka J., Yashiro M., Sakurai K., Kubo N., Tanaka H., Muguruma K., et al. Role of the stemness factors Sox2, Oct3/4, and nanog in gastric carcinoma. J. Surg. Res 2012, 174:130-135.
84. Wang Q., He W., Lu C., Wang Z., Wang J., Giercksky K.E., et al. Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma. Anticancer Res 2009, 29:1233-1241.
85. Yu F., Li J., Chen H., Fu J., Ray S., Huang S., et al. Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene 2011, 30:2161-2172.
86. Pera M. The dark side of pluripotency. Nature 2011, 471:46-47.
87. Gore A., Li Z., Fung H.L., Young J.E., Agarwal S., Antosiewicz-Bourget J., et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011, 471:63-67.
88. Hussein S.M., Batada N.N., Vuoristo S., Ching R.W., Autio R., Narva E., et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011, 471:58-62.
89. Lister R., Pelizzola M., Kida Y.S., Hawkins R.D., Nery J.R., Hon G., et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011, 471:68-73.
90. Yilmazer A., de Lazaro I., Bussy C., Kostarelos K. In vivo cell reprogramming towards pluripotency by virus-free overexpression of defined factors. PLoS ONE 2013, 8:e54754.
91. Yilmazer A., de Lazaro I., Bussy C., Kostarelos K. In vivo reprogramming of adult somatic cells to pluripotency by overexpression of Yamanaka factors. J. Vix. Exp 2013, 17:e50837.